{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:57:01Z","timestamp":1772848621910,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.pcad.2019.10.004","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T11:14:55Z","timestamp":1572002095000},"page":"384-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lipid management beyond the guidelines"],"prefix":"10.1016","volume":"62","author":[{"given":"Jennifer G.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.pcad.2019.10.004_bb0005","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"25, Part B","key":"10.1016\/j.pcad.2019.10.004_bb0010","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2013","journal-title":"J Am Coll Cardiol. 2014"},{"key":"10.1016\/j.pcad.2019.10.004_bb0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation."},{"issue":"39","key":"10.1016\/j.pcad.2019.10.004_bb0020","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"European Heart Journal"},{"issue":"suppl 2","key":"10.1016\/j.pcad.2019.10.004_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and preventionof cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"16","key":"10.1016\/j.pcad.2019.10.004_bb0030","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCULATIONAHA.116.022134","article-title":"Moving toward the next paradigm for cardiovascular prevention","volume":"133","author":"Robinson","year":"2016","journal-title":"Circulation."},{"issue":"22","key":"10.1016\/j.pcad.2019.10.004_bb0035","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1161\/CIR.0000000000000042","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on performance measures and task force on practice guidelines","volume":"129","author":"Anderson","year":"2014","journal-title":"Circulation."},{"issue":"24","key":"10.1016\/j.pcad.2019.10.004_bb0040","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"Journal of the American College of Cardiology. 2019"},{"issue":"1","key":"10.1016\/j.pcad.2019.10.004_bb0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2015.7248","article-title":"Proprotein convertase subtilisin\/kexin type 9 (pcsk9) inhibitors for treatment of high cholesterol levels: effectiveness and value","volume":"176","author":"Tice","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.pcad.2019.10.004_bb0050","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacl.2019.05.005","article-title":"Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit: a statement from the National Lipid Association","volume":"13","author":"Robinson","year":"2019","journal-title":"J CLin Lipidol."},{"key":"10.1016\/j.pcad.2019.10.004_bb0055","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis","volume":"319","author":"Navarese (Co-primary) EP","year":"2018","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.pcad.2019.10.004_bb0060","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2019.10.004_bb0065","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.amjcard.2014.08.009","article-title":"Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy","volume":"114","author":"Puri","year":"2014","journal-title":"Am J Cardiol"},{"issue":"22","key":"10.1016\/j.pcad.2019.10.004_bb0070","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA."},{"issue":"37","key":"10.1016\/j.pcad.2019.10.004_bb0075","article-title":"Coronary artery plaque imaging","volume":"19","author":"Xie","year":"2017","journal-title":"Curr Atheroscler Rep"},{"issue":"43","key":"10.1016\/j.pcad.2019.10.004_bb0080","first-page":"2984","article-title":"Requiem for the \u2018vulnerable plaque\u2019","volume":"36","author":"Libby","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2019.10.004_bb0085","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.amjcard.2006.06.039","article-title":"Identifying patients for aggressive cholesterol lowering: the risk curve concept","volume":"98","author":"Robinson","year":"2006","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1016\/j.pcad.2019.10.004_bb0090","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"New England Journal of Medicine."},{"issue":"4","key":"10.1016\/j.pcad.2019.10.004_bb0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1016\/j.pcad.2019.10.004_bb0100","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New England Journal of Medicine."},{"issue":"1","key":"10.1016\/j.pcad.2019.10.004_bb0105","first-page":"11","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019"},{"issue":"3","key":"10.1016\/j.pcad.2019.10.004_bb0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2019.10.004_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n\u22123 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"NEJM."},{"key":"10.1016\/j.pcad.2019.10.004_bb0120","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2019.10.004_bb0125","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"The ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2019.10.004_bb0130","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2019.10.004_bb0135","article-title":"Additive Therapies for Cardiovascular Disease: Effectiveness and Value","author":"Ollendorf","year":"2019","journal-title":"Institute for Clinical and Economic Review"},{"issue":"2","key":"10.1016\/j.pcad.2019.10.004_bb0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/M17-0681","article-title":"Comparison of five major guidelines for statin use in primary prevention in a contemporary general population","volume":"168","author":"Mortensen","year":"2018","journal-title":"Ann Intern Med"},{"issue":"25, Part B","key":"10.1016\/j.pcad.2019.10.004_bb0145","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.pcad.2019.10.004_bb0150","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.jacc.2018.11.005","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology","volume":"73","author":"Lloyd-Jones","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2019.10.004_bb0155","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/M14-1281","article-title":"An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort calibration and discrimination among CVD risk scores","volume":"162","author":"DeFilippis","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2019.10.004_bb0160","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/M16-1739","article-title":"Calibration of the pooled cohort equations for atherosclerotic cardiovascular diseasean updatecalibration of the pooled cohort equations for ASCVD","volume":"165","author":"Cook","year":"2016","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1016\/j.pcad.2019.10.004_bb0165","first-page":"598","volume":"38","author":"DeFilippis","year":"2017","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.pcad.2019.10.004_bb0170","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jamainternmed.2018.2875","article-title":"Evaluation of the pooled cohort risk equations for cardiovascular risk prediction in a multiethnic cohort from the women's health initiative","volume":"178","author":"Mora","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"14","key":"10.1016\/j.pcad.2019.10.004_bb0175","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2014.2630","article-title":"Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations","volume":"311","author":"Muntner","year":"2014","journal-title":"JAMA."},{"issue":"7","key":"10.1016\/j.pcad.2019.10.004_bb0180","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/eurheartj\/ehy653","article-title":"Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies","volume":"40","author":"Pennells","year":"2019","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1016\/j.pcad.2019.10.004_bb0185","first-page":"e29","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2019.10.004_bb0190","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.atherosclerosis.2016.01.017","article-title":"Coronary artery calcium predicts cardiovascular events in participants with a low lifetime risk of cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"246","author":"Joshi","year":"2016","journal-title":"Atherosclerosis."},{"issue":"13","key":"10.1016\/j.pcad.2019.10.004_bb0195","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1136\/heartjnl-2017-312151","article-title":"Sex differences in impact of coronary artery calcification to predict coronary artery disease","volume":"104","author":"Nakao","year":"2018","journal-title":"Heart."},{"issue":"5","key":"10.1016\/j.pcad.2019.10.004_bb0200","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamacardio.2016.1326","article-title":"Recent trends in cardiovascular mortality in the United States and public health goals","volume":"1","author":"Sidney","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.pcad.2019.10.004_bb0205","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.jcmg.2017.09.003","article-title":"Coronary artery calcium and long-term risk of death, myocardial infarction, and stroke: the Walter reed cohort study","volume":"11","author":"Mitchell","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2019.10.004_bb0210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2018.08.040","article-title":"Optimising treatment of hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk","volume":"278","author":"Soran","year":"2018","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.pcad.2019.10.004_bb0215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet."},{"issue":"7247","key":"10.1016\/j.pcad.2019.10.004_bb0220","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1136\/bmj.320.7247.1446","article-title":"Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey","volume":"320","author":"Steel","year":"2000","journal-title":"Br Med J"},{"key":"10.1016\/j.pcad.2019.10.004_bb0225","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2019.03.529","article-title":"Associations between blood pressure and cholesterol during young adulthood and cardiovascular events later in life","volume":"14","author":"Zhang","year":"2019","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"10.1016\/j.pcad.2019.10.004_bb0230","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/jamacardio.2016.0991","article-title":"RIsk of premature cardiovascular disease vs the number of premature cardiovascular events","volume":"1","author":"Sniderman","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2019.10.004_bb0235","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/M17-0996","article-title":"TRends in racial\/ethnic and nativity disparities in cardiovascular health among adults without prevalent cardiovascular disease in the United States, 1988 to 2014","volume":"168","author":"Brown","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2019.10.004_bb0240","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009778","article-title":"Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein B lipoproteins earlier in life","volume":"7","author":"Robinson","year":"2018","journal-title":"J Am Heart Assoc"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003306201930129X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003306201930129X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:16:34Z","timestamp":1758500194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003306201930129X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S003306201930129X"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2019.10.004","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid management beyond the guidelines","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2019.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}